Drug maker, Cadila Healthcare has said that the company`s US arm has obtained tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atomoxetine Hydrochloride capsules.

The said drug would be available in the strengths of 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg respectively.

Atomoxetine Hydrochloride Capsules are generic equivalent to Strattera of Eli Lily and company. The capsules are indicated for treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults and falls under the neurological (CNS) segment. The product has a market size of approximately USD 500 million for the twelve months ending March 2009 according to Newport.

Shares of the company declined Rs 0.35, or 0.06%, to trade at Rs 550. The total volume of shares traded was 1,586 at the BSE (11.36 a.m., Wednesday).